OS after transplantation. (A) OS after transplantation between Group A and Groups B and C (n = 814). (B) OS after transplantation comparing Groups A, B, and C (n = 814). (C) OS after intervention for MRD between Groups B and C (n = 105). A total of 709 subjects were MRD⁻ after transplantation (Group A); 105 subjects were MRD⁺ after transplantation (Groups B and C); 49 subjects received IL-2 (Group B) and 56 subjects received DLI (Group C).